Long-term survival of patients with metastatic melanoma (MM) treated with dacarbazine (DTIC) or temozolomide (TMZ)

被引：0
|
作者：
Kim, C.
Lee, C. W.
Klasa, R.
Shah, A.
Savage, K. J.
机构：
[1] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[2] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9054
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Long-Term Survival in Patients with Metastatic Melanoma Treated with DTIC or Temozolomide
    Kim, Christina
    Lee, Christopher W.
    Kovacic, Laurel
    Shah, Amil
    Klasa, Richard
    Savage, Kerry J.
    ONCOLOGIST, 2010, 15 (07): : 765 - 771
  • [2] Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine
    Hersh, E.
    Weber, J.
    Powderly, J.
    Pavlik, A.
    Nichol, G.
    Yellin, M.
    Cranmer, L.
    Urba, W.
    O'Day, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Long-term survival after glioblastoma multiforme treated by concurrent temozolomide (TMZ) and radiotherapy?
    Micke, O.
    Schaefer, U.
    Schueller, P.
    Willich, N.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 : 51 - 52
  • [4] Long-term survival after glioblastoma multiforme, treated by concurrent temozolomide (TMZ) and radiotherapy?
    Micke, O.
    Schaefer, U.
    Schueller, P.
    Willich, N.
    NEURO-ONCOLOGY, 2006, 8 (04) : 311 - 311
  • [5] Is long-term survival after glioblastoma multiforme treated by concurrent Temozolomide (TMZ) and radiotherapy possible?
    Micke, O.
    Schaefer, U.
    Schueller, P.
    Willich, N.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2008, 184 : 142 - 142
  • [6] A randomized trial of dacarbazine (DTIC) versus dacarbazine-carboplatin (DTIC-CBDCA) in patients with metastatic melanoma
    Babovic, Nada
    Matkovic, Suzana
    Kreacic, Miroslav
    Jelic, Svetislav
    ANNALS OF ONCOLOGY, 2004, 15 : 203 - 203
  • [7] Mismatch repair (MMR) and base excision repair (BER) protein expression correlates with clinical response to dacarbazine (DTIC)/temozolomide (TMZ) therapy of patients with metastatic melanoma.
    Sobol, R. W., Jr.
    Tawbi, H.
    Jukic, D. M.
    Mule, K.
    Mascari, R.
    Kirkwood, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 456S - 456S
  • [8] Continuous temozolomide (TMZ) monotherapy as first-line treatment in patients with metastatic melanoma (MM)
    del Pozo, N.
    Blasco, A.
    Camps, C.
    Caballero, C.
    Estevez Garcia, P.
    Jantus, E.
    Marin, S.
    Oliver, V.
    Berrocal, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] LONG-TERM COMPLETE REMISSIONS IN PATIENTS WITH DISSEMINATED MELANOMA TREATED BY FOTEMUSTINE AND DACARBAZINE
    OLIVER, V
    ALIAGA, A
    LOPEZ, JJL
    PEREZ, E
    PONCHON, A
    BIZZARI, JP
    COUR, V
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (02) : 287 - 287
  • [10] PROGNOSTIC FACTOR FOR LONG-TERM SURVIVAL AFTER GLIOBLASTOMA MULTIFORME TREATED BY CONCURRENT TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY
    Micke, O.
    Schaefer, U.
    Bruns, F.
    Buentzel, J.
    Willich, N.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4079 - 4079
12345